Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 16/20 | 0.39 |
| ▸ | CTSK | P43235 | 14/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21175428 | 1.00 | CTSS (0.39) | CTSSCTSKCTSLCTSBCA14 | |
| SCHEMBL343493 | 0.85 | CTSS (0.38) | CTSSCTSKCTSLCTSBHDAC6 | |
| SCHEMBL343494 | 0.85 | CTSS (0.38) | CTSSCTSKCTSLCTSBHDAC6 | |
| SCHEMBL21192610 | 0.84 | SMN1; SMN2 (0.32) | CTSSCTSKHDAC1HDAC2HDAC6 | |
| SCHEMBL20014820 | 0.84 | SMN1; SMN2 (0.32) | CTSSCTSKHDAC1HDAC2HDAC6 | |
| SCHEMBL16812742 | 0.82 | CTSK (0.37) | CTSSCTSKCTSLCTSBHDAC1 | |
| SCHEMBL18281954 | 0.82 | CTSS (0.34) | CTSSCTSKCA14HDAC1HDAC2 | |
| SCHEMBL18285697 | 0.81 | CA14 (0.37) | CTSSCTSKCA14HDAC1HDAC2 | |
| SCHEMBL28478854 | 0.81 | CTSS (0.33) | CTSSCTSKCTSLCTSB | |
| SCHEMBL23564375 | 0.81 | CTSL (0.37) | CTSSCTSKCTSLCTSBCA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4097099-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11926643-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-08 | — | — | US | disclosed |
| CN-115698003-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | CTSS 4743/4885CTSK 4144/4885CTSL 4570/4885 |
| US-11926643-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | CTSS 2856/4885CTSK 2553/4885CTSL 2203/4885 |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CTSS 2856/4885CTSK 2553/4885CTSL 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.